Literature DB >> 6198297

An in vitro study on the effects of isoprinosine on immune responses in cancer patients.

K Y Tsang, H H Fudenberg, J F Pan, M J Gnagy, C B Bristow.   

Abstract

The in vitro effects of ISO on the immune responses of cancer patients were investigated. Forty seven patients with primary tumors (26 lung carcinoma, 14 breast adenocarcinoma, 7 melanoma) were studied. Concanavalin A (ConA)-induced lymphocyte proliferation, natural killer cell (NK) activity, and monocyte chemotaxis were measured. In 40 of the 47 patients (85%), ConA-induced lymphocyte proliferation was depressed; NK activity was depressed in 32 (68%), and monocyte chemotaxis was found to be depressed in 36 (77%). For in vitro studies, an optimum concentration of ISO (100 micrograms/ml per 10(6) cells) was used to treat peripheral blood mononuclear cells. In the presence of ISO, all three parameters were restored to normal or near normal levels in those that were depressed. Under these preincubation conditions in vitro treatment of mononuclear cells from the peripheral blood of normal individuals with ISO had no effect on their activities in the three assays. Similar effects on these three immune parameters were observed when 24 h supernatants obtained from patients' mononuclear cells pretreated with ISO were employed in these assays.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6198297     DOI: 10.1016/0192-0561(83)90041-3

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  4 in total

1.  Partial restoration of impaired interleukin-2 production and Tac antigen (putative interleukin-2 receptor) expression in patients with acquired immune deficiency syndrome by isoprinosine treatment in vitro.

Authors:  K Y Tsang; H H Fudenberg; G M Galbraith; R P Donnelly; L R Bishop; W R Koopmann
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

Review 2.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

Review 3.  WITHDRAWN: Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.

Authors:  Andre D Sasse; Emma C Sasse; Luciana Go Clark; Otavio Augusto Camara Clark
Journal:  Cochrane Database Syst Rev       Date:  2018-02-06

Review 4.  Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.

Authors:  Jiri Sliva; Chrysoula N Pantzartzi; Martin Votava
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.